Bexionpharma
1 known investors
Find your way into Bexionpharma
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing biologic cancer therapies that target dysregulated sphingolipid metabolism to counter tumor survival and treatment resistance. Its lead program, BXQ-350, is being studied in patients with advanced solid tumors, including metastatic colorectal cancer.
Founders & leadership
SS
Scott ShivelyinFounder
Investors · 1
Competitors · 2
by search overlapBioworld25 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Lexicon Pharmaceuticals17 shared keywordsLexicon Pharmaceuticals develops and commercializes pharmaceutical products, including the marketed drug INPEFA and drug candidates in clinical development such as sotagliflozin, pilavapadin, and LX9851, serving patients in need of treatments across various therapeutic areas.
Companies competing with Bexionpharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Bexionpharma do?
- Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing biologic cancer therapies that target dysregulated sphingolipid metabolism to counter tumor survival and treatment resistance. Its lead program, BXQ-350, is being studied in patients with advanced solid tumors, including metastatic colorectal cancer.
- Who founded Bexionpharma?
- Bexionpharma was founded by Scott Shively.
- Who are Bexionpharma's investors?
- Bexionpharma's investors include Keyhorse Capital.